- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12. | H.C. Wainwright senkt Kursziel für Werewolf Therapeutics nach Pipeline-Update drastisch | 10 | Investing.com Deutsch | ||
| 19.12. | H.C. Wainwright slashes Werewolf Therapeutics stock price target on pipeline update | 2 | Investing.com | ||
| 18.12. | Werewolf Therapeutics, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
| 04.11. | Werewolf Therapeutics reports Q3 results | 10 | Seeking Alpha | ||
| WEREWOLF THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.11. | Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.11. | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.10. | Werewolf Therapeutics Says FDA Grants Fast Track For WTX-124 In Advanced Melanoma Treatment | 4 | RTTNews | ||
| 08.10. | Werewolf Therapeutics receives FDA Fast Track for melanoma therapy | 3 | Investing.com | ||
| 08.10. | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | 304 | GlobeNewswire (Europe) | Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:... ► Artikel lesen | |
| 06.10. | Todesfall im Verwaltungsrat: Werewolf Therapeutics erfüllt NASDAQ-Regeln für Prüfungsausschuss nicht mehr | 8 | Investing.com Deutsch | ||
| 06.10. | Werewolf Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.10. | Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.08. | Citizens JMP lowers Werewolf Therapeutics stock price target to $3 from $4 | 5 | Investing.com | ||
| 14.08. | Werewolf Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 14.08. | Werewolf Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 06.08. | Werewolf Therapeutics celebrates 'Full Moon Moments' in clinical trial recruitment push | 6 | FiercePharma | ||
| 09.07. | Werewolf Therapeutics, Inc.: Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit | 6 | GlobeNewswire (USA) | ||
| 08.05. | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 351 | GlobeNewswire (Europe) | - WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking... ► Artikel lesen | |
| 17.04. | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer | 462 | GlobeNewswire (Europe) | WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of... ► Artikel lesen | |
| 11.03. | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 477 | GlobeNewswire (Europe) | - Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | +3,14 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| EVOTEC | 5,388 | +3,10 % | Anhaltender Druck im Biotech-Sektor: Evotec weiter unter Druck: Kritische Kurszone rückt in den Fokus | Die Aktie von Evotec befindet sich weiterhin in einer angespannten Lage. Der Kurs bewegt sich nur noch knapp oberhalb eines technisch wichtigen Bereichs, während operative Schwächen, der Rückzug relevanter... ► Artikel lesen | |
| BB BIOTECH | 49,200 | -0,10 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,025 | +16,67 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| MODERNA | 27,580 | -9,19 % | Forget Moderna Stock, This is a Much Better Buy | ||
| VALNEVA | 3,654 | -1,77 % | Wochenend-Analyse: Valneva-Aktie vor entscheidender Woche - Montag könnte alles ändern! | ||
| NOVAVAX | 5,766 | -2,24 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 146,80 | -2,23 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,000 | -3,69 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| 4SC | 0,086 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,430 | -0,69 % | Bionxt Solutions Inc: Bionxt Solutions talks up sublingual thin-film product | ||
| INFLARX | 0,938 | +0,48 % | InflaRx N.V.: InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 | JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,810 | +3,37 % | Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) | ||
| BAVARIAN NORDIC | 25,010 | -0,08 % | Bavarian Nordic A/S: Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees | COPENHAGEN, Denmark, December 18, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management... ► Artikel lesen |
Das Unternehmen WEREWOLF THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,92 % bei einem Aktienkurs von 0,654 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WEREWOLF THERAPEUTICS INC finden Sie auf Wallstreet Online.